Long-term outcome of acute promyelocytic leukemia treated with all-<i>trans</i>-retinoic acid, arsenic trioxide, and gemtuzumab.
Abaza, Yasmin; Kantarjian, Hagop; Garcia-Manero, Guillermo; Estey, Elihu; Borthakur, Gautam; Jabbour, Elias; Faderl, Stefan; O'Brien, Susan; Wierda, William; Pierce, Sherry; Brandt, Mark; McCue, Deborah; Luthra, Rajyalakshmi; Patel, Keyur; Kornblau, Steven; Kadia, Tapan; Daver, Naval; DiNardo, Courtney; Jain, Nitin; Verstovsek, Srdan; Ferrajoli, Alessandra; Andreeff, Michael; Konopleva, Marina; Estrov, Zeev; Foudray, Maria; McCue, David; Cortes, Jorge; Ravandi, Farhad.
; 129(10): 1275-1283, 2017 03 09.
Artigo em Inglês | MEDLINE | ID: mdl-28003274
First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid.
Current standard treatment of adult acute promyelocytic leukaemia.
Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
Optimal treatment strategies for high-risk acute promyelocytic leukemia.
Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide.
Current management of newly diagnosed acute promyelocytic leukemia.
ATRA + ATO: has a new standard of care been established in low-risk acute promyelocytic leukaemia?
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.
Retinoic acid plus arsenic trioxide, the ultimate panacea for acute promyelocytic leukemia?